A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Completed · Phase 2 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA).

Key facts

Study ID

NCT01225393

Run by

Genentech, Inc.

People needed

211

Starts

2010-11-01

Last updated by the study team

2016-11-02

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of RA according to the 1987 revised ACR Criteria for the Classification of RA for at least 6 months prior to screening
• Positive for rheumatoid factor or anti-cyclic citrullinated peptide (CCP) antibody, or both
• Active disease, defined as: CRP >= 1.0 mg/dL; swollen joint count >= 6 (66 joint count); tender joint count >= 6 (68 joint count)
• Previous inadequate clinical response to at least one disease-modifying anti-rheumatic drug (DMARD) consisting of either methotrexate (MTX) or leflunomide (LFU)
• For patients currently receiving corticosteroids: Treatment at a stable dose during last 4 weeks prior to screening
• For patients currently receiving non-steroidal anti-inflammatory drugs (NSAIDs): Treatment at a stable dose during last 4 weeks prior to screening
• For patients currently receiving sulfasalazine or anti-malarials: Treatment initiated and continued for at least the last 6 months prior to screening and on a stable dose
• For patients of reproductive potential (males and females): Willing to use a highly effective birth control method for the duration of the study according to local guidelines

You may not qualify if…

• Pregnant, planning to become pregnant during the study, or breastfeeding
• Clinically significant abnormal laboratory values or abnormal ECG or vital signs
• History of anaphylactic reactions
• Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome), however patients with secondary Sjogren's syndrome are eligible for the study
• History of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthritis, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, or other overlap syndrome)
• Current or recent (within 4 weeks prior to screening) infection, including signs, symptoms or serology of any infection, including HIV, hepatitis B or C, tuberculosis
• Administration of a live, attenuated vaccine within 1 month before dosing or anticipation that such a live attenuated vaccine will be required during the study
• Previous treatment with anti-TNF biologics or other biologic agents, including anti-CD20-directed therapy (e.g. rituximab), anti-IL6-directed therapy (e.g. tocilizumab), or T cell-directed therapy (e.g. abatacept)

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Peoria, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Upland, California, United States
• Study site — Ormond Beach, Florida, United States
• Study site — Lexington, Kentucky, United States
• Study site — Kalamazoo, Michigan, United States
• Study site — Flowood, Mississippi, United States
• Study site — Reno, Nevada, United States
• Study site — Charleston, South Carolina, United States
• Study site — San Antonio, Texas, United States
• Study site — Chesapeake, Virginia, United States
• Study site — Clarksburg, West Virginia, United States
• Study site — Sofia, Bulgaria
• Study site — Sofia, Bulgaria
• Study site — Sofia, Bulgaria
• Study site — Santiago, Chile
• Study site — Santiago, Chile
• Study site — Santiago, Chile
• Study site — Bad Nauheim, Germany
• Study site — Berlin, Germany
• Study site — Cologne, Germany
• Study site — Erfurt, Germany
• Study site — Freiburg im Breisgau, Germany
• Study site — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.